Search

News RETRO-TAS Study –⁠ Trifluridine/Tipiracil in Pretreated mCRC in Real-World Practice

How does trifluridine/tipiracil (FTD/TPI), which demonstrated efficacy in clinical trials in chemotherapy-refractory metastatic colorectal cancer (mCRC), fare in real-world practice? This was investigated by the authors of the Greek retrospective observational study RETRO-TAS.

Source: Treatment of Gastrointestinal Carcinomas 25. 5. 2023

News Morning Myopic Shift and Glare in Patients with Advanced Fuchs Endothelial Corneal Dystrophy

A newly published study by a German team analyzes the morning and afternoon differences in various parameters in patients with Fuchs endothelial corneal dystrophy to determine which of them contribute to subjective visual difficulties in the morning.

Source: Glaucoma 8. 6. 2020

News Scientists Create First Functional Brain Tissue Using 3D Printing

A research team from the University of Wisconsin-Madison has successfully printed the first ever functional brain tissue using a commercial 3D printer in their laboratory. This breakthrough may be beneficial not only for scientists studying the pathogenesis of neurological and neurodevelopmental diseases but could even mark the beginning of a journey towards a deeper understanding of how neurons function, how brain development occurred, and how different parts of the brain communicate with each other.

Source: 9. 4. 2024

News Distribution and Localization of Specifically Modified Exosomes Can Improve the Treatment of Muscular Dystrophies

A research team from several Milanese universities, in a study published in Nature Nanotechnology, focused on developing a new method for muscular dystrophy therapy. Specifically modified exosomes were enriched with the protein annexin A1 and delivered into dystrophic muscle cells using ferromagnetic nanotubes guided by an external magnetic field. This triggered healing processes in damaged cells and tissues in a mouse model.

Source: 3. 12. 2024

News Can Artificial Intelligence Help Personalize Treatment for Cardiology Patients?

According to data from the World Health Organization (WHO), cardiovascular diseases (CVDs) claim an estimated 17.9 million lives annually worldwide, making them the leading cause of death. More than 4 out of 5 of these deaths are due to heart attacks and strokes, and one-third occur in people under the age of 70. An innovative project called NextGen will newly address cardiovascular diseases. Its goal is to use artificial intelligence (AI) and patient health information and genetic profiles to personalize their treatment. The project received 7.6 million euros from the EU program Horizon Europe and will be led by a 21-member consortium including representatives from the European Society of Cardiology (ESC).

Source: 16. 5. 2024

News The Importance of Vitamin D for the Proper Function of the Immune System

The relationship between vitamin D and the immune system has been known for nearly 30 years, but only in recent years have we gained new insights that explain and further refine the physiological role of vitamin D in the functioning of the human immune system.

Source: GI, colic and microbiome 29. 3. 2021

News Hydroresponsive Dressings for Acute and Hard-to-Heal Wounds

A recently published review of clinical evidence from nearly three dozen studies demonstrates successful debridement and cleansing of various hard-to-heal wounds using HydroClean hydroresponsive dressing, with favorable healing outcomes.

Source: Wound Healing 4. 8. 2022

News Comparison of the Efficacy of Tofacitinib and Vedolizumab in the Treatment of Ulcerative Colitis After Anti-TNF Therapy Failure

Therapeutic options for ulcerative colitis resistant to anti-TNF-α antibody treatment are available, but there were no studies comparing the selective immunosuppressants tofacitinib and vedolizumab in this patient population. The aim of this comparison was a multicenter French study, the first results of which were presented at the 17th ECCO Congress 2022.

Source: Intestinal Inflammations 21. 8. 2022

News Bite-Sized Pieces from EHA 2021: Two New Findings on T-Cell Lymphoma

Can a molecule that is crucial for the sensitivity of adult T-cell lymphoma or leukemia (ATLL) to NK cell cytotoxicity be identified? And what conclusions were drawn from the testing of an antibody specific for TRBC1 in the investigation of T-lymphoproliferative disorders? These topics were also covered at the EHA 2021 congress, in the electronic poster presentation section.

Source: Hematologic Malignancies 15. 12. 2021

News Intestinal Gel LECIG in the Treatment of Advanced Parkinson's Disease in Real Practice

A recently published study presents the first experiences with an intestinal gel containing a triple combination of antiparkinsonian drugs and dosed via an infusion pump through percutaneous endoscopic gastrostomy extended into the jejunum in the treatment of advanced Parkinson's disease.

Source: Parkinson's Disease 10. 3. 2023

News Treatment with Dupilumab in Severe Corticosteroid-Dependent Bronchial Asthma –⁠ A Case Study

We present the case of a 36-year-old woman with severe corticosteroid-dependent asthma with numerous comorbidities and complications due to long-term systemic corticosteroid therapy. Significant improvements in quality of life, asthma control, regression of skin changes in atopic dermatitis, and reduction in methylprednisolone consumption for this patient were only achieved after the initiation of biological treatment. Dupilumab, a monoclonal antibody against the α subunit of the receptor for interleukins IL-4 and IL-13, which is approved for the treatment of severe refractory eosinophilic bronchial asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis, was indicated in her treatment.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 4. 4. 2022

News Testing RAS Gene Mutations in Patients with Colorectal Cancer

Correct identification of the RAS oncogene variant is crucial for deciding the treatment of patients with colorectal cancer. Information on the prevalence of individual RAS gene mutations varies significantly in the literature, which may be due to different testing methods. The authors of the presented analysis focused on how the approach to testing RAS variants has evolved over time in Europe.

Source: Colorectal Cancer 17. 5. 2020

News Effect of Combination of Dorzolamide with Timolol for Wet Age-Related Macular Degeneration

In some eyes with wet age-related macular degeneration (AMD), exudation does not stop despite frequent intravitreal injections of vascular endothelial factor blockers (anti-VEGF). Adjuvant therapy that reduces edema may improve overall treatment outcomes concerning visual functions. A recently published multicenter randomized clinical study evaluated the effect of local therapy combining dorzolamide and timolol in patients with this issue.

Source: Glaucoma 3. 7. 2020

News Effect of Telmisartan and Losartan on Bone Turnover Markers in Patients with Newly Diagnosed Stage I Hypertension

Telmisartan, an AT1 receptor blocker for angiotensin II and partial agonist of the PPAR-γ receptor, is a widely used antihypertensive. The PPAR-γ receptor plays a role in the genesis of osteoblasts and osteoclasts, and antidiabetic drugs from the thiazolidinedione group, which act as agonists of this receptor, have a known inhibitory effect on bone metabolism and increase the risk of non-traumatic fractures. Knowledge regarding the potential similar effects of telmisartan is limited. The following study compared the effects of telmisartan and losartan (an AT1 blocker without agonistic effect on PPAR-γ) on bone turnover markers in patients with newly diagnosed hypertension.

Source: Sartans in the Treatment of Hypertension 12. 8. 2021

News Expanded Hemodialysis as an Alternative to Hemodiafiltration

Expanded hemodialysis is a new type of therapy that effectively removes middle molecules from the blood of dialysis patients. The aim of the Spanish authors was to compare its efficiency with hemodiafiltration in terms of clearance of middle molecules in an open randomized clinical study.

Source: Chronic Kidney Disease 9. 12. 2021